Chapter 1 - Human genome epidemiology: the road map revisited
This website is archived for historical purposes and is no longer being maintained or updated.
Human Genome Epidemiology (2nd ed.): Building the evidence for using genetic information to improve health and prevent disease
necessarily represent the views of the funding agency.”
Muin J. Khoury, Sara R. Bedrosian, Marta Gwinn, Julian Little, Julian P. T. Higgins, and John P. A. Ioannidis
Examples of emerging applications of human genome discoveries for clinical practice and disease prevention
|Type of Application||Examples of Proposed Applications|
|Therapeutic agents||Herceptin in treatment of breast cancer|
|Diagnostic tests||BRCA analysis in hereditary breast and ovarian cancer|
|Pharmacogenomic tests||Genetic testing for warfarin treatment|
|Prognostic tests||Tumor gene expression profiles in various cancers|
|Screening tests||Biomarkers for early detection of ovarian cancer|
|Risk assessment tests||Genome profiles in breast and prostate cancer|
Human genome epidemiology and the phases of genomics translation: examples and application
|Phase||Notation||Types of Research||Examples|
|T1||Discovery to candidate health application.||Phases 1 and 2 clinical trials; observational studies.||What is the magnitude of the association between genetic variants and disease risks? Is there gene-environment interaction?|
|T2||Health application to evidence-based practice guidelines.||Phase 3 clinical trials; observational studies; evidence synthesis and guidelines development.||What are the positive and negative predictive values of genetic factors in risk assessment?|
|T3||Practice guidelines to health practice.||Dissemination research; implementation research; diffusion research; Phase 4 clinical trials.||What proportion of individuals who meet guidelines criteria receive recommended care and what are the barriers to implementing practice guidelines?|
|T4||Practice to population health impact.||Outcomes research (includes many disciplines); population monitoring of morbidity, mortality, benefits and risks.||Does implementation of practice guidelines reduce disease incidence/improve outcomes?|
Source: Adapted from Reference 28.
See Reference 28 for definition of terms.
- Page last reviewed: January 6, 2010 (archived document)
- Content source: